ArticleNature communications2023
Aromatized liposomes for sustained drug delivery.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 98 citations in OpenAlex.
- Unsaturated phospholipids form multicompartment liposomes that extend release of hydrophilic drugs.Nature biomedical engineering · 2026Article
- Ultra-slow release of hydrophilic drugs via multilamellar-multivesicular liposomes formed by unsaturated phospholipids.Nature biomedical engineering · 2026Article
- Peptide Coacervates as Dynamic and Interactive Depots for Tetrodotoxin in Long-Acting Local Anesthesia.Advanced healthcare materials · 2026Article
- Cyclodextrin Nanosponge-PVA Hybrid Networks as Supramolecular Reservoir Systems for Amitriptyline.ACS omega · 2026Article
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Polymerized Pro-Estrogen Microneedles via Two Photon Polymerization.Macromolecular rapid communications · 2026Article
- Tumor-targeted liposomal RNAi therapy suppresses breast cancer and modulates tumor microenvironment.Journal of nanobiotechnology · 2026Article
- High Drug Encapsulation Capacity in Cyclodextrin-Based Nanoparticles: Characterization andACS bio & med chem Au · 2026Article
- Strategies for overcoming multiple barriers of oral administration of protein and peptide therapeutics.Materials today. Bio · 2026Review
- Epigenetic regulation in cancer metastasis.Discover oncology · 2026Review
- Extended local anesthesia enabled by flavonoid permeation enhancers.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Biofunctional alginate hydrogel enabling Fe³⁺ detection and therapeutic modulation of hepatic fibrosis.Mikrochimica acta · 2026Article
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.Pharmaceutics · 2026Article
- Self-synergizing mutual prodrug liposomes for targeted cancer therapyTheranostics · 2026Article
- Injectable Microparticle-Nanoliposome Hydrogel for Extended Release of Small Hydrophilic Molecules.ACS nano · 2025Article
- Visible light-induced controlled release and biological evaluation of bismuth sulfide quantum dots and silver nanoparticles co-sensitized titanium dioxide nanotubes.Materials today. Bio · 2025Article
- Prodrug nanosystem equipped with a sonosensitizer for combined chemotherapy and sonodynamic therapy of melanoma.Materials today. Bio · 2025Article
- Unlocking the potential of remdesivir: innovative approaches to drug delivery.Drug delivery and translational research · 2025Review
- Enhanced Control of Liposomal Drug Release by Drug-Aptamer Complexes.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Formation and evaluation of docetaxel and triptolide polymer micelles for anti-cancer activity.Nanomedicine (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Insufficient drug loading and leakage of payload remain major challenges in designing liposome-based drug delivery systems. These phenomena can limit duration of effect and cause toxicity. Targeting the rate-limiting step in drug release from liposomes, we modify (aromatized) them to have aromatic groups within their lipid bilayers. Aromatized liposomes are designed with synthetic phospholipids with aromatic groups covalently conjugated onto acyl chains. The optimized aromatized liposome increases drug loading and significantly decreases the burst release of a broad range of payloads (small molecules and macromolecules, different degrees of hydrophilicity) and extends their duration of release. Aromatized liposomes encapsulating the anesthetic tetrodotoxin (TTX) achieve markedly prolonged effect and decreased toxicity in an application where liposomes are used clinically: local anesthesia, even though TTX is a hydrophilic small molecule which is typically difficult to encapsulate. Aromatization of lipid bilayers can improve the performance of liposomal drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.